These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 1411865)
21. Human recombinant erythropoietin in the treatment of anaemia in chronic haemodialysis patients. Sulková S; Kvasnicka J; Kasl M; Kozlová J; Podrouzek P; Bartûsková J; Válek A Czech Med; 1990; 13(2-3):98-106. PubMed ID: 2245762 [TBL] [Abstract][Full Text] [Related]
22. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group. Nissenson AR Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075 [TBL] [Abstract][Full Text] [Related]
23. Importance of iron status monitoring during erythropoietin treatment in uremic predialysis patients. Rutkowski B; Debska-Slizień A; Biedunkiewicz B; Bułło B Ann Univ Mariae Curie Sklodowska Med; 1994; 48 Suppl 3():17-21. PubMed ID: 8192528 [TBL] [Abstract][Full Text] [Related]
24. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. Eschbach JW; Egrie JC; Downing MR; Browne JK; Adamson JW N Engl J Med; 1987 Jan; 316(2):73-8. PubMed ID: 3537801 [TBL] [Abstract][Full Text] [Related]
25. Blood rheology and hypertension in hemodialysis patients treated with erythropoietin. Schaefer RM; Leschke M; Strauer BE; Heidland A Am J Nephrol; 1988; 8(6):449-53. PubMed ID: 3218658 [TBL] [Abstract][Full Text] [Related]
26. Impaired erythrocyte fluidity during treatment of renal anaemia with erythropoietin. Linde T; Sandhagen B; Danielson BG; Wikström B J Intern Med; 1992 Jun; 231(6):601-6. PubMed ID: 1619383 [TBL] [Abstract][Full Text] [Related]
27. Changes in rheology and red blood cell function under recombinant human erythropoietin therapy. Schmidt R; Lerche D; Dörp E; Winkler R; Klinkmann H Pol Arch Med Wewn; 1991 Jun; 85(6):384-90. PubMed ID: 1896402 [TBL] [Abstract][Full Text] [Related]
28. The effect of recombinant human erythropoietin on hemostatic status in chronic uremic patients. Tsao CJ; Kao RH; Cheng TY; Huang CC; Chang SL; Lee FN Int J Hematol; 1992 Apr; 55(2):197-203. PubMed ID: 1511168 [TBL] [Abstract][Full Text] [Related]
30. Rheological studies during treatment of renal anaemia with recombinant human erythropoietin. Macdougall IC; Davies ME; Hutton RD; Coles GA; Williams JD Br J Haematol; 1991 Apr; 77(4):550-8. PubMed ID: 2025581 [TBL] [Abstract][Full Text] [Related]
31. Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. Casati S; Passerini P; Campise MR; Graziani G; Cesana B; Perisic M; Ponticelli C Br Med J (Clin Res Ed); 1987 Oct; 295(6605):1017-20. PubMed ID: 3120854 [TBL] [Abstract][Full Text] [Related]
32. [The effect of treatment with human recombinant erythropoietin on the functional status of patients on maintenance hemodialysis]. Ermolenko VM; Lashutin SV; Rudakov AG; Fel'd BN; Manakova TE; Kukhtevich AV; Kondakhchan MA; Romanenko NG Ter Arkh; 1991; 63(6):81-6. PubMed ID: 1948755 [TBL] [Abstract][Full Text] [Related]
33. [Erythropoietin, blood viscosity and hypertension in chronic kidney failure]. Schaefer RM; Heidland A Dtsch Med Wochenschr; 1989 Jun; 114(26):1046-9. PubMed ID: 2661190 [No Abstract] [Full Text] [Related]
34. The clinical effects of recombinant human erythropoietin for the treatment of anemia in end stage renal disease patients on dialysis. Uthayanaka Y; Jirajan B; Krairithichai U; Jantavanich N Southeast Asian J Trop Med Public Health; 1993 Sep; 24(3):577-82. PubMed ID: 8160072 [TBL] [Abstract][Full Text] [Related]
35. [Treatment of anemia in hemodialyzed children using recombinant human erythropoietin (Eprex). Results of a French multicenter clinical trial]. Gagnadoux MF; Loirat C; Berthélémé JP; Maisin A; Kamoun A; Dabout D; Poisson D; Broyer M Nephrologie; 1994; 15(3):207-11. PubMed ID: 7969713 [TBL] [Abstract][Full Text] [Related]
36. Oxidative injury to erythrocytes, cell rigidity and splenic hemolysis in hemodialyzed patients before and during erythropoietin treatment. Zachée P; Ferrant A; Daelemans R; Coolen L; Goossens W; Lins RL; Couttenye M; De Broe ME; Boogaerts MA Nephron; 1993; 65(2):288-93. PubMed ID: 8247195 [TBL] [Abstract][Full Text] [Related]
37. [Clinical studies of recombinant human erythropoietin in patients on long-term dialysis]. Ji SM; Li LS; Ji DX Zhonghua Nei Ke Za Zhi; 1993 Feb; 32(2):100-2. PubMed ID: 8404323 [TBL] [Abstract][Full Text] [Related]
38. [The blood rheological indices of patients with necrobiosis lipoidica]. Petrova GA; Levin GIa Vestn Dermatol Venerol; 1989; (12):45-8. PubMed ID: 2633553 [TBL] [Abstract][Full Text] [Related]
39. Effect of erythropoietin treatment on tissue oxygenation in patients with severe transfusion dependent renal anaemia. Landgraf H; Grützmacher P; Garcia-Bartels C; Bergmann M; Ehrly AM; Schoeppe W Eur J Med; 1993; 2(7):393-7. PubMed ID: 8258026 [TBL] [Abstract][Full Text] [Related]
40. Effects of recombinant human erythropoietin on porphyrin metabolism in uremic patients on hemodialysis. Fontanellas A; Herrero JA; Coronel F; Santos JL; Morán MJ; Barrientos A; Enríquez de Salamanca R J Am Soc Nephrol; 1996 May; 7(5):774-9. PubMed ID: 8738813 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]